New combo therapy aims to fight inoperable liver cancer

NCT ID NCT06485466

Recruiting now Disease control Sponsor: Guohui Xu Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether adding two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. The study will enroll 101 participants with intermediate or advanced liver cancer. The goal is to see if the combination delays cancer growth compared to the drugs alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camrelizumab and apatinib combined with transarterial chemoembolization (TACE)
What this could lead to: If successful, this combination could offer a new, more effective treatment option for people with liver cancer that cannot be surgically removed, potentially slowing disease progression.
What could go wrong: This is an early-phase trial with only 101 participants, so results may not apply to everyone. The combination therapy also carries risks like liver damage, bleeding, and immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APATINIB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APATINIB CAMRELIZUMAB TRANSARTERIAL CHEMOEMBOLIZATION UNRESECTABLE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Sichuan Cancer Hospital and Research Institute
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.